Aspira Women’s Health Inc.
(formerly known as Vermillion, Inc.
Nasdaq: VRML) is transforming women’s health with the discovery
, development, and commercialization of innovative
testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1®plus combines our FDA-cleared products OVA1® and OVERA® to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiXSM testing offers both targeted and a more comprehensive genetic testing options with a gynecologic focus. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment. Could be worth a watch.